340B

On Friday, September 12, 2025, the U.S. Court of Appeals for the Fifth Circuit issued an unpublished decision upholding a Mississippi law that protects 340B contract pharmacy arrangements. The ruling came in [...]

Feldesman Partner Marcie H. Zakheim will present two sessions at the 2025 Nebraska Community Health Conference, hosted by the Health Center Association of Nebraska (HCAN), on September 8–9, 2025 in Nebraska City, [...]

On August 1, 2025, the Office of Pharmacy Affairs (OPA) of the Health Resources and Services Administration (HRSA) announced a pilot rebate program for purchases under the 340B drug discount statute of [...]

Feldesman Partners Gabriel García and Jacki Leifer will present at the 2025 Annual Conference and Health Care Provider Retreat, co-hosted by the New Mexico Primary Care Association and New Mexico Health Resources, [...]

Feldesman Partner Steve Kuperberg will speak at the 340B Grantees Spring Conference, taking place from May 29 – 30 in Kansas City, MO. On May 30, Mr. Kuperberg will present “340B Legal Focus: [...]

Key Challenges Still Loom for Covered Entities On Monday, May 12, the White House issued an Executive Order (EO) aimed at addressing  prescription drug prices. The EO opens with a remarkable [...]

On April 15, President Trump signed an Executive Order reviving a previous directive to reduce the cost of insulin and injectable epinephrine for low income individuals. The Executive Order instructs the Secretary [...]

“Eternal vigilance is the price of liberty.”  – quote attributed to Thomas Jefferson and John Philpot Curran Over the past two years, nearly three dozen states have considered legislation requiring drug manufacturers [...]

The new second term Trump Administration, barely a month old, has stirred controversy through a lightning-fast review of federal spending, in some cases attempting to freeze trillions of dollars in already-appropriated federal [...]

As a new Congress and Administration begin a dizzying series of initiatives, health centers and others participating in the federal 340B drug discount statute understandably crave predictions regarding 340B’s future. Not only [...]